https://doi.org/10.4081/reumatismo.2013.219

Insight into the WNT system and its drug related response

Vol. 65 No. 5 (2013)
Submitted: 8 July 2013
Accepted: 7 November 2013
Published: 18 December 2013
WNT, DKK1, Sclerostin, Bisphosphonate.
Abstract Views: 3053
PDF: 1038
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

S. Tamanini
silvia.tamanini@yahoo.it
Rheumatology Unit, University of Verona, Italy.
L. Idolazzi
Rheumatology Unit, University of Verona, .
D. Gatti
Rheumatology Unit, University of Verona, Italy.
O. Viapiana
Rheumatology Unit, University of Verona, Italy.
A. Fassio
Rheumatology Unit, University of Verona, Italy.
M. Rossini
Rheumatology Unit, University of Verona, Italy.
The WNT signalling pathway is a complex system for transferring information for DNA expression from the cell surface receptors to cytoplasm and then to the nucleus. It is based on several proteins that work together as agonists and antagonists in order to maintain homeostasys and to promote anabolic processes. The WNT system acts on all cellular lines involved in bone resorption and formation. WNT pathway can mainly be triggered by two different signalling cascades. The first is well known and is the so-called WNT-beta catenin system (or the canonical pathway), the second is known as the non canonical WNT pathway. WNT proteins form a superfamily of secreted glycoproteins. The association with surface receptors, called Frizzled, that are members of the G protein-coupled receptors superfamily and co receptors like low-density lipoprotein receptor-related proteins 5 and 6 (LRP5/6) complete the WNT system. LRP5/6 show high affinity for WNT antagonists that modulate the activity of this pathway: DKK1 and sclerostin (SCL), that play a crucial role in modulating the WNT system. The WNT-pathway and in particular its antagonists SCL and DKK1 seems to play a key role in the regulation of bone remodeling during treatment with bone active agents such as bisphosphonates, but not only. Their effects become relevant especially in the course of long-term treatments.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
S. Tamanini, Rheumatology Unit, University of Verona
L. Idolazzi, Rheumatology Unit, University of Verona
D. Gatti, Rheumatology Unit, University of Verona
O. Viapiana, Rheumatology Unit, University of Verona
A. Fassio, Rheumatology Unit, University of Verona
M. Rossini, Rheumatology Unit, University of Verona

How to Cite

Tamanini, S., Idolazzi, L., Gatti, D., Viapiana, O., Fassio, A., & Rossini, M. (2013). Insight into the WNT system and its drug related response. Reumatismo, 65(5), 219–230. https://doi.org/10.4081/reumatismo.2013.219

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.